A patient with atrial fibrillation and a mechanical heart valve asks about switching from warfarin to apixaban. The cardiologist advises against this because DOACs fail in mechanical valves primarily due to:

• A DOACs cannot achieve adequate INR monitoring targets required for mechanical valve anticoagulation
• B Mechanical heart valves generate high shear stress activating thrombin amplification pathways beyond factor Xa and thrombin that require vitamin K-dependent factor suppression; RE-ALIGN trial showed higher thromboembolic and bleeding rates with dabigatran vs. warfarin ✓
• C DOACs have short half-lives requiring dosing intervals incompatible with maintenance of continuous mechanical valve anticoagulation
• D DOACs do not adequately inhibit platelet activation on metallic valve surfaces

Explanation

The RE-ALIGN trial (dabigatran vs. warfarin in mechanical valve patients) was stopped early due to more strokes, TIA, and thromboembolic events, as well as more bleeding with dabigatran. The hypothesized mechanism is that mechanical heart valves create turbulent flow and foreign surface-mediated coagulation that activates the full coagulation cascade, requiring broader suppression (as warfarin achieves by inhibiting factors II, VII, IX, X, protein C and S). Targeting only thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban) is insufficient. All current guidelines (ACC/AHA, ESC) contraindicate DOACs in mechanical valves.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.